Research Outputs

Permanent URI for this communityhttps://hdl.handle.net/20.500.14288/2

Browse

Filters

20101

Advanced Search

Filter by

Settings

Department: search.filters.department.Department of Chemical and Biological EngineeringSubject: search.filters.subject.Industrial engineering

Search Results

Now showing 1 - 1 of 1
  • Placeholder
    PublicationMetadata only
    Structure based drug design for insulin degrading enzyme (IDE)
    (AICHE, 2010) Department of Industrial Engineering; Department of Chemical and Biological Engineering; Department of Chemical and Biological Engineering; Türkay, Metin; Kızılel, Seda; Kavaklı, İbrahim Halil; Dağlıyan, Onur; Dağyıldız, Ezgi; Çakır, Bilal; Faculty Member; Faculty Member; Faculty Member; Master Student; PhD Student; PhD Student; Department of Industrial Engineering; Department of Chemical and Biological Engineering; College of Engineering; College of Engineering; College of Engineering; Graduate School of Sciences and Engineering; Graduate School of Sciences and Engineering; Graduate School of Sciences and Engineering; 24956; 28376; 40319; N/A; N/A; N/A
    Insulin-degrading enzyme (IDE) is an allosteric Zn +2 metalloprotease involved in the degradation of many peptides including amyloid beta (Aβ), and insulin that play key roles in Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM), respectively. Crystal structure of IDE revealed that N-terminal of IDE has an exosite which serves as a regulation site by orientation of the substrates of IDE to the catalytic site. It is plausible to find small molecules that bind to the exosite of IDE and enhance its proteolytic activity towards different substrates. In this study, we have taken a computer-aided structure based drug design methods combined with experimental methods, one novel molecule that enhances the activity of human IDE was discovered. The novel compound, designated as D10 enhanced both IDE mediated proteolysis of substrate V and insulin degradation. This study describes the first examples of a computer-aided discovery of IDE regulators, showing that in vitro activation of this important enzyme with drug-like small molecules is attainable.